TIMOTHY CURRAN, PhD
IQ Consortium Board of Directors Member (2019-Present)
IQ Active Pharmaceutical Ingredients (now Drug Substance) Leadership Group (DSLG) Chair (2018-2019)
IQ DSLG Member(2012-Present)
IQ DSLG Nitrosamines Working Group Chair (2019-Preseent)

Senior Director, Vertex
PhD, Organic Chemistry , Purdue University

WHAT FACTORS SHAPED THE GROWTH OF IQ?

Changes in the industry shape IQ – whether it is new scientific findings or pressure from regulatory changes. As scientists we strive to be out in front of some of these changes, but oftentimes we cannot predict how agencies respond or see what will force change in certain directions.

WHAT ARE YOUR FONDEST MEMORIES SO FAR?

Among my fondest memories are the face-to-face meetings, summits, and symposia, and the discussions regarding issues within the pharma industry. There is tremendous impact when we, as a team of industrial scientists, align on the best practices for us all. As an industry, we achieve significant gains when scientific consensus is reached based on scientific results. The industry advances through healthy and generous collaboration and the appropriate sharing of information on a range of best practices.

WHAT COMES NEXT FOR IQ IN THE NEXT TEN YEARS?

IQ is recognized as the leading science-based association representing the pharmaceutical industry. The timely and collaborative work of IQ has led to this recognition. For example, IQ’s work in a range of areas such as pediatric formulations, nitrosamines, and other projects, continues to guide the pharmaceutical industry and is beginning to impact other industries. IQ’s impact has in some ways just begun; IQ must continue to do great work based on science and expand relationships with global regulators, all with the goal of better serving the patient.